solid rais
bottom line one stock frequent look rel inexpens
manag abil string togeth seri consist good quarter
elus possibl chang deliv solid beat rais despit
difficult y/i comp mani pipelin product begin gain traction
begin see benefit cost initi put place year ago
oper margin expand bp y/i reiter outperform
rais tp
revenu ex-fx surpass consensuss includ
cvg group revenu ex-fx diabet revenu
ex-fx restor therapi ex-fx minim invas
therapi group revenu ex-fx gross margin decreas
y/i includ hit fx sg decreas significantli
 rel flat oper margin increas
impress y/i ep beat consensuss
takeaway spine franchis continu benefit mazor pull-through
opportun combin spine/en technolog sale increas
 world-wide dcb sale declin area
rang show sign slow recoveri tavr sale increas mid-teen
y/i manag estim risk expand market opportun
diabet revenu increas strong ou sale offset competit
headwind product pipelin robust upcom launch includ
surgic robot micra av leadless pacemak reveal linq cardiac monitor
system evolut tavr
manag reiter revenu guidanc organ rais
cvg guidanc mitg maintain rtg
guidanc lower diabet lower end ep guidanc
increas incorpor beat
minu fx benefit quarter revers later year plu
benefit debt refinanc increas ep
introduc ep
pleas refer page import disclosur includ analyst certif
therapi diabet franchis along
healthi cash flow dividend yield valuat
make compel invest
good sold
sale
 sale
chang incl fx impact
target price base cash ep
product launch heart valv
segment addit roll-out mazor spine
robot system surgic robot expand
respect market captur addit share
face stiffer competit market
stent tavr market fail fulli captur
expect cost save enterpris excel initi
usd
expect launch micra av
evolut tavr valv robot
assist surgeri platform minim
diversifi compani focus
cardiovascular spine neuromodul diabet
product includ icd pacemak diagnost
monitor devic electrophysiolog system
cardiovascular product includ coronari peripher
stent valv replac product stent graft
solid rais
one stock frequent look rel inexpens manag abil
string togeth seri consist good quarter elus possibl chang
compani deliv solid beat rais face one difficult comp
mani pipelin product begin gain traction begin
see benefit cost initi put place year ago sg decreas
one primari driver bp oper margin expans bp constant
currenc reiter outperform rais target price base
ep
turn back quarter revenu ex-fx surpass consensuss
includ cvg group revenu ex-fx versu street diabet
revenu ex-fx versu consensuss restor therapi
ex-fx ahead consensuss minim invas therapi group revenu
ex-fx versu street
regard expens gross margin decreas y/i includ hit fx
sg decreas significantli rel flat oper
margin increas impress y/i ep beat consensuss
manag reiter revenu guidanc organ rais cvg guidanc
mitg maintain rtg guidanc lower
diabet lower end ep guidanc increas
incorpor beat minu fx benefit quarter revers later
year plu benefit debt refinanc
compani report factset streetaccount bmo capit market estim
compani report bmo capit market
medtron result confirm slowdown spinal cord stimul market total pain
therapi revenu ex-fx get segment specif
manag provid certain sudoku detail help us piec togeth franchis
know pain stimul segment includ db declin low-doubl
digit reflect slowdown franchis inventori destock compani
comment implant posit y/i
compani report market model estim market
declin ww market declin market estim share
flat y/i manag admit none market particip realli come
forward realist explan market slow dramat
heighten inventori field like start toward explan other product
pipelin key driver futur implant market growth innov plan
unveil next-gener intelli devic well new stimul pattern nan
januari la vega come forward time new omnia
devic full launch wavewrit product enhanc
hope stimul market pun intend
tavr continu growth driver contribut estim
geographi manag commentari indic segment deliv mid-teen
growth ou look forward expect momentum wane
august fda approv risk indic expand address patient popul
manag estim market expans could much updat nation
coverag decis ncd could result new tavr center come on-line
alreadi negoti half uptak evolut continu launch
evolut pend
chang previou guidancecurr margin -- y/i declin sg -- modest improv -- slightli oper marginsslight improv impli margin y/i impli margin chang previou guidancetax oper non-oper per quarterprevi per quartercash vascular /-minim invas therapi therapi chang previou guidanc diabet grouplow-singl digitslow end diabet franchis perform somewhat better expect revenu
ahead street million manag lower fy guidanc lower end
 revenu declin mid-singl digit due competit pressur like benefit
tandem tough y/i comp retent rate near histor
averag manag commentari new patient add lower expect given
competit product offer outlin american diabet associ ada analyst event
manag look recov lost patient add launch minim
latest hybrid close loop system auto-bolu featur blue tooth capabl allow futur
algorithm updat ou sale ex-fx driven expand launch minim
spine franchis continu see resurg follow acquisit mazor robot system
sale increas combin enabl technolog rose
includ highest rate nine quarter manag would provid detail
mazor system placement quarter cite competit reason comment see
pull-through opportun implant sale also capit sale sale
stealthstat navig system y/i o-arm surgic imag system close
last two new system spine market indic real leverag portfolio
look forward believ capit sale momentum sustain five-year
implant contract hospit provid nice annuity-lik busi model
spine franchis help return above-market growth
within brain therapi neurovascular franchis hum given new product adopt
increas mid- rang compani appear capit full suit
devic strong adopt solitair stent retriev riptid aspir system
react aspir cathet consist convers neurosurgeon
comment medtron abil cross-sel aspir stent retriev tool one
comprehens packag aspir market specif manag comment
exit market share high teen
paclitaxel dcb headwind persist seem bottom
medtron report dcb revenu declin area world-wide
rang expect go-forward y/i declin
headwind anniversari march better initi declin
dcb manufactur first indic manag comment improv
outlook driven fda august letter reconfirm benefit/risk balanc
technolog case volum increas releas letter increas
confid physician impact admir data indic limit class
effect paclitaxel issu physician differenti product look forward manag
confid receiv approv av fistula indic given data
present cirs septemb barcelona may earli agre
actual timelin av fistula indic especi given delay becton dickinson btk
indic note confid manag portray sinc june fda panel
topic could begin slow recoveri saw coronari de back
million except per-shar good expens incom includ mt non-oper expens interest expens incom attribut non-control ep w/ option net ep w/ option w/ analysisnet margin percentag chang sequenti net gross oper pre-tax net chang annual net net sale net sale gross oper pre-tax net ep w/ option ex-
 dt ronic ra ing hist ori
ct dickinson nd com pa ny ra ing hist ori
bost scie nt ific ra ing hist ori
ne vro ra ing hist ori
ta nde dia ca inc ra ing hist ori
